Regeneron Pharmaceuticals, Inc. REGN
Set alert
As of Nov 2, 10:26 AM ET
- YTD
- +24.29%
- 1 year
- +47.19%
- Open
- 927.22
- Prev close
- 927.89
- Mkt cap
- 99.39B
- Vol
- 487.91K
- Avg vol
- 733.95K
- EPS
- 45.24
- P/E
- 21.24
- Div yield
- 0.46%
More statistics
- Low
- 927.00
- High
- 972.06
- Forward P/E
- 14.74
- Beta
- 0.15
- Short ratio
- 2.78
- Inst. own
- 93.18%
- Dividend
- 3.76
- Ex-div date
- Aug 17, 2026
- Earnings
- Jan 28, 2027
- 50-d avg
- 791.28
- 200-d avg
- 736.67
- 1y target
- 869.07
YTD chart
Events in this range
- Jan 30, 2026Earnings: 11.44; estimate 10.74; surprise 6.52%
- Feb 20, 2026Dividend: 0.94
- Apr 29, 2026Earnings: 9.47; estimate 8.91; surprise 6.29%
- May 20, 2026Dividend: 0.94
- Jul 30, 2026Earnings: 14.29; estimate 10.16; surprise 40.65%
- Aug 18, 2026Dividend: 0.94
- Oct 7, 2026Rating: Truist Securities · Buy → Buy
- Oct 8, 2026Rating: RBC Capital · Sector Perform → Sector Perform
- Oct 15, 2026Rating: UBS · Neutral → Buy
- Oct 19, 2026Rating: Piper Sandler · Overweight → Overweight
- Oct 21, 2026Rating: TD Cowen · Buy → Buy
- Oct 28, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 30, 2026Earnings: 20.07; estimate 16.51; surprise 21.56%
Signals (47)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| RSI: Overbought | Sep 2, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| RSI: Overbought | Jul 30, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 23, 2026 | 3 months ago |
| SMA: Bullish | Jul 7, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 5, 2026 | 5 months ago |
| RSI: Oversold | May 27, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| RSI: Oversold | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 12, 2026 | 5 months ago |
| RSI: Oversold | Apr 29, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 24, 2026 | 6 months ago |
| SMA: Bullish | Apr 23, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 23, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 15, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Apr 8, 2026 | 6 months ago |
| SMA: Bearish | Apr 2, 2026 | 7 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 5, 2026 | 8 months ago |
| SMA: Bullish | Mar 4, 2026 | 8 months ago |
| SMA: Bearish | Mar 3, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 24, 2026 | 8 months ago |
| SMA: Bullish | Feb 11, 2026 | 8 months ago |
| SMA: Bearish | Feb 10, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 4, 2026 | 9 months ago |
| SMA: Bullish | Feb 3, 2026 | 9 months ago |
| SMA: Bearish | Jan 28, 2026 | 9 months ago |
| SMA: Bullish | Jan 21, 2026 | 9 months ago |
| SMA: Bearish | Jan 16, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 8, 2026 | 9 months ago |
Key statistics
- Market cap
- 95.31B
- Enterprise value
- 76.47B
- Trailing P/E
- 22.89
- Forward P/E
- 14.74
- PEG ratio
- 1.40
- Price / sales
- 6.14
- Price / book
- 2.93
- EPS (TTM)
- 40.44
- Beta
- 0.15
- Dividend yield
- 0.46%
- Payout ratio
- 9.00%
- Profit margin
- 27.87%
- Revenue (TTM)
- 15.53B
- Revenue growth
- 16.70%
- Free cash flow
- 3.07B
- Total cash
- 7.99B
- Total debt
- 2.71B
- Return on equity
- 14.04%
- Shares outstanding
- 101.14M
- Short % of float
- 2.19%
- 50-day average
- 791.28
- 200-day average
- 736.67
Analyst view
Consensus: buy
- Target (low)
- 730.00
- Target (mean)
- 869.07
- Target (high)
- 1,030.00
- Strong buy4
- Buy15
- Hold8
- Sell0
- Strong sell1
Next earnings
Jan 28, 2027
Expected Jan 28, 2027. Consensus EPS estimate 20.50.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 28, 2027 | Dec 30, 2026 | 24.25 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 16.51 | 20.07 | +3.56 | +21.56% |
| Jul 30, 2026 | Jun 30, 2026 | 10.16 | 14.29 | +4.13 | +40.65% |
| Apr 29, 2026 | Mar 31, 2026 | 8.91 | 9.47 | +0.56 | +6.29% |
| Jan 30, 2026 | Dec 31, 2025 | 10.74 | 11.44 | +0.70 | +6.52% |
| Oct 28, 2025 | Sep 30, 2025 | 9.65 | 11.83 | +2.18 | +22.59% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 21, 2026 | TD Cowen | main | Buy | Buy |
| Oct 19, 2026 | Piper Sandler | main | Overweight | Overweight |
| Oct 15, 2026 | UBS | up | Neutral | Buy |
| Oct 8, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 7, 2026 | Truist Securities | main | Buy | Buy |
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- regeneron.com
News
- Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1100
- These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results
- These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results
- Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $925
- Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter
- Evercore ISI Group Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1075
- Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
- Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
- Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1175
- Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $980
Your note
Sign in to keep a note on REGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROWN MICHAEL S | Director | Stock Award(Grant) | Jan 1, 2026 | 12,865 |
| FENIMORE CHRISTOPHER R | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 17, 2026 | 23,505 |
| LAROSA JOSEPH J | General Counsel | Conversion of Exercise of derivative security | Aug 18, 2026 | 45,595 |
| MCCOURT MARION E | Officer | Stock Award(Grant) | Dec 4, 2025 | 15,567 |
| MURPHY ANDREW J | Officer | Stock Award(Grant) | Dec 4, 2025 | 56,437 |
| RYAN ARTHUR F. | Director | Sale | Jul 1, 2026 | 17,303 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.01% | 9,113,506 | 8.44B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.56% | 6,629,759 | 6.14B | Jun 29, 2026 |
| Dodge & Cox Inc. | 4.82% | 4,871,137 | 4.51B | Jun 29, 2026 |
| State Street Corporation | 4.78% | 4,834,688 | 4.48B | Jun 29, 2026 |
| Invesco Ltd. | 3.90% | 3,940,665 | 3.65B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 3.73% | 3,774,199 | 3.49B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.23% | 3,270,896 | 3.03B | Jun 29, 2026 |
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 3.09% | 3,121,304 | 2.89B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.56% | 2,588,231 | 2.40B | Jun 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.09% | 2,112,569 | 1.96B | Sep 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.29% | 1,306,480 | 1.21B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.28% | 1,297,077 | 1.20B | Aug 30, 2026 |